{"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.0001","statisticalComment":"stratified by age group and region","statisticalMethod":"Log Rank"},{"ciLowerLimit":"0.429","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.724","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Hazard Ratio (HR)","paramValue":"0.557","statisticalComment":"stratified by age group and region","statisticalMethod":"Regression, Cox"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"283","upperLimit":"451","value":"337"},{"groupId":"OG001","lowerLimit":"160","upperLimit":"238","value":"175"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"207"},{"groupId":"OG001","value":"210"}],"units":"Participants"}],"description":"Time to progression was defined at the time (days) from randomization to progression (based on central assessment \\[radiological and clinical progression due to bone irradiation\\])","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received 2 tablets of Sorafenib (2×200 mg) orally twice daily (12 hours apart without food), 28 days comprise a cycle","id":"OG000","title":"Sorafenib (Nexavar, BAY43-9006)"},{"description":"Participants received 2 tablets of Sorafenib-matching placebo orally twice daily (12 hours apart without food), 28 days comprise a cycle","id":"OG001","title":"Placebo"}],"paramType":"MEDIAN","populationDescription":"FAS","reportingStatus":"POSTED","timeFrame":"From randomization of the first subject until the database cut-off (31 Aug 2012), study duration approximately three years","title":"Time to Progression (TTP) Based on Central Assessment Incl. Clinical Progression Due to Bone Irradiation","type":"SECONDARY","unitOfMeasure":"Days"}